Atritech-B (06669.HK) Surges Over 12% on Strategic Collaboration Agreements with Boston Scientific

According to the Zhitong Finance APP, Acotec Medical-B (06669) surged over 12%. As of press time, it rose by 12.41%, trading at HK$12.86, with a turnover of HK$1.7861 million.

On the news front, Acotec announced that it signed a cooperation framework agreement and a service framework agreement with Boston Scientific on July 20. The framework agreement signed this time mainly reflects a series of cooperation that the two parties will carry out in the fields of global commercialization of products, product manufacturing services, and product development over the next three years. It is reported that the signing of this cooperation framework agreement and service framework agreement will further promote the implementation of the synergistic value of both parties.

According to the cooperation framework agreement, in the Chinese market, both parties will adopt a cross-selling cooperation model. In specific overseas markets, Boston Scientific Corporation has obtained exclusive distribution rights for selected Acotec products (the first batch of selected products includes peripheral drug-coated balloons, peripheral thrombus aspiration systems, endovenous radiofrequency ablation systems, and coronary PTCA (Percutaneous Transluminal Coronary Angioplasty) balloon dilation catheters, etc.).